
Qiagen N.V. – NYSE:QGEN
Qiagen N.V. stock price today
Qiagen N.V. stock price monthly change
Qiagen N.V. stock price quarterly change
Qiagen N.V. stock price yearly change
Qiagen N.V. key metrics
Market Cap | 9.94B |
Enterprise value | 10.92B |
P/E | 107.62 |
EV/Sales | 5.55 |
EV/EBITDA | 30.84 |
Price/Sales | 5.07 |
Price/Book | 2.83 |
PEG ratio | 50.58 |
EPS | 1.52 |
Revenue | 1.93B |
EBITDA | 687.62M |
Income | 336.94M |
Revenue Q/Q | -5.48% |
Revenue Y/Y | -2.99% |
Profit margin | 4.73% |
Oper. margin | 5.92% |
Gross margin | 49.66% |
EBIT margin | 5.92% |
EBITDA margin | 35.47% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeQiagen N.V. stock price history
Qiagen N.V. stock forecast
Qiagen N.V. financial statements
$49
Potential upside: 1.87%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 494.85M | 80.78M | 16.33% |
---|---|---|---|
Sep 2023 | 475.89M | 77.81M | 16.35% |
Dec 2023 | 509.16M | 97.66M | 19.18% |
Mar 2024 | 458.79M | 80.67M | 17.58% |
Jun 2023 | 6347268000 | 2.72B | 42.91% |
---|---|---|---|
Sep 2023 | 5906698000 | 2.21B | 37.47% |
Dec 2023 | 6115190000 | 2.30B | 37.73% |
Mar 2024 | 5805929000 | 2.20B | 38% |
Jun 2023 | 111.47M | 156.27M | -15.47M |
---|---|---|---|
Sep 2023 | 124.68M | 248.36M | -401.09M |
Dec 2023 | 151.36M | -58.45M | -7.43M |
Mar 2024 | 133.07M | 6.43M | -292.08M |
Qiagen N.V. alternative data
Sep 2023 | 6,100 |
---|---|
Oct 2023 | 6,100 |
Nov 2023 | 6,100 |
Dec 2023 | 6,000 |
Jan 2024 | 6,000 |
Feb 2024 | 6,000 |
Mar 2024 | 5,191 |
Apr 2024 | 5,191 |
May 2024 | 5,191 |
Jun 2024 | 5,900 |
Jul 2024 | 5,900 |
Qiagen N.V. other data
Quarter | Transcript |
---|---|
Q1 2024 30 Apr 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 11 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 31 Oct 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 9 Aug 2023 | Q2 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. Thierry Bernard (1965) Chief Executive Officer, MD & Member of Management Board | $2,410,000 |
Dr. Roland Sackers (1968) Chief Financial Officer, MD & Member of Management Board | $977,500 |
Lab Instrument Industry Update - New Commercial Entrants
Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence
Qiagen: Fantastic Growth At A Reasonable Price Pick
Qiagen Offers Growth And Margin Leverage Beyond The Pandemic Deceleration
Charles River Laboratories International: A Great Business At A Decent Price
Invitae Busted Business Model Offers A Tactical Opportunity
-
What's the price of Qiagen N.V. stock today?
One share of Qiagen N.V. stock can currently be purchased for approximately $48.1.
-
When is Qiagen N.V.'s next earnings date?
Unfortunately, Qiagen N.V.'s (QGEN) next earnings date is currently unknown.
-
Does Qiagen N.V. pay dividends?
Yes, Qiagen N.V. pays dividends and its trailing 12-month yield is 2.93% with 0% payout ratio. The last Qiagen N.V. stock dividend of $1.08 was paid on 31 Jan 2017.
-
How much money does Qiagen N.V. make?
Qiagen N.V. has a market capitalization of 9.94B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 8.23% to 1.97B US dollars.
-
What is Qiagen N.V.'s stock symbol?
Qiagen N.V. is traded on the NYSE under the ticker symbol "QGEN".
-
What is Qiagen N.V.'s primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of Qiagen N.V.?
Shares of Qiagen N.V. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Qiagen N.V.'s key executives?
Qiagen N.V.'s management team includes the following people:
- Mr. Thierry Bernard Chief Executive Officer, MD & Member of Management Board(age: 60, pay: $2,410,000)
- Dr. Roland Sackers Chief Financial Officer, MD & Member of Management Board(age: 57, pay: $977,500)
-
How many employees does Qiagen N.V. have?
As Jul 2024, Qiagen N.V. employs 5,900 workers, which is 14% more then previous quarter.
-
When Qiagen N.V. went public?
Qiagen N.V. is publicly traded company for more then 29 years since IPO on 28 Jun 1996.
-
What is Qiagen N.V.'s official website?
The official website for Qiagen N.V. is qiagen.com.
-
How can i contact Qiagen N.V.?
Qiagen N.V. can be reached via phone at +31 77 355 6600.
-
What is Qiagen N.V. stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Qiagen N.V. in the last 12 months, the avarage price target is $49. The average price target represents a 1.87% change from the last price of $48.1.
Qiagen N.V. company profile:

Qiagen N.V.
qiagen.comNYSE
5,800
Medical - Diagnostics & Research
Healthcare
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Venlo, 5912 PL
CIK: 0001015820
ISIN: NL0015001WM6
CUSIP: N72482123